drugset / Trial / NCT06078800
A Study of YL-17231 in Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is a phase 1 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of oral YL-17231 in patients with advanced solid tumors with KRAS mutation, so as to confirm the recommended phase 2 dose of YL-17231 and obtain the preliminary efficacy information of patients with advanced solid tumors with KRAS mutation.
Timeline
- Start
- 2023-09-28
- Primary completion
- 2025-03
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YL-17231 | Unknown | 0.25 mg | Oral |
| Subject | YL-17231 | Unknown | 0.5 mg | Oral |
| Subject | YL-17231 | Unknown | 10 mg | Oral |